Latest News and Press Releases

World’s leading psychedelic conference kicks off with workshops from leaders in science, medicine, therapy, policy, Indigenous medicine, and societyUpcoming deadline: speaker submissions, initial...

After three years of negotiation with the FDA, MAPS has successfully secured FDA clearance to conduct a clinical trial, MJP2, to examine the use of smoked cannabis for the treatment of PTSD symptoms...

MAPS, which has incubated and funded cutting-edge psychedelic research for decades, is continuing to advance our understanding of psychedelic-assisted therapiesThis study is one of the first trials...

MAPS remains confident in its goal of making access to MDMA-assisted therapy for PTSD safe and legal SAN JOSE, Calif., Aug. 09, 2024 (GLOBE NEWSWIRE) -- The Multidisciplinary Association for...

WASHINGTON, May 01, 2024 (GLOBE NEWSWIRE) -- What: The Multidisciplinary Association for Psychedelic Studies (MAPS), The Marijuana Policy Project (MPP), and the National Organization for the...

MAPS uses its over 30 years of experience in the psychedelic space to offer a first-of-its-kind gold-standard training program.

MAPS, which celebrates its 38th anniversary on April 8, will celebrate with a total solar eclipse at the Texas Eclipse 2024 festival in Texas

SAN JOSE, Calif. , Feb. 13, 2024 (GLOBE NEWSWIRE) -- The Multidisciplinary Association for Psychedelic Studies (MAPS) has announced that the Psychedelic Science 2025 Conference will convene in the...

The FDA has accepted Lykos Therapeutics' New Drug Application, supported by two decades of research incubated by MAPS, for MDMA-assisted therapy for PTSD.

To date, MAPS has supported nearly 70 organizations worldwide to advance charitable projects in the psychedelic movementCurrently, MAPS serves as a fiscal sponsor for 10 organizations in the newly...